Evidence map›Paper›PMID 26552755›Full record

Trial reportHeart (British Cardiac Society)2016

Dabigatran etexilate and reduction in serum apolipoprotein B.

Philip Joseph, Guillaume Pare, Lars Wallentin, Stuart Connolly, Salim Yusuf, Jia Wang, Michael Ezekowitz, John Eikelboom, Agneta Siegbahn, Paul Reilly and 3 more

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Heart (British Cardiac Society), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Observational
  5. Article
  6. Review
  7. Review
  8. Dabigatran and apolipoprotein B.Heart (British Cardiac Society) · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Philip JosephPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Guillaume ParePopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Lars WallentinDepartment of Medical Sciences, Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden.
Stuart ConnollyPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Salim YusufPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Jia WangPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Michael EzekowitzJefferson Medical College, Wynnewood, Pennsylvania, USA.
John EikelboomPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Agneta SiegbahnDepartment of Medical Sciences, Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden.
Paul ReillyDepartment of Clinical Development and Clinical Biostatistics, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA.
Ellison ThemelesPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Jonas OldgrenDepartment of Medical Sciences, Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden.
RE-LY Investigators
McMaster University · CAUppsala University · SEPopulation Health Research Institute · CABoehringer Ingelheim (United States) · USJefferson College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCarboxylesterases, which convert dabigatran etexilate to its active form, dabigatran, have also been shown to influence lipoprotein metabolism, although any pleotropic effects of the drug based on this possible mechanism has not been evaluated. We examined the effects of dabigatran etexilate on serum lipoprotein markers in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study.

methods2513 participants from the RE-LY randomised control trial with baseline and 3-month apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1) measurements were included. We prospectively compared the effects of dabigatran 110 mg twice daily, dabigatran 150 mg twice daily and warfarin on changes in ApoB and ApoA1 concentrations using a mixed model analysis.

resultsFrom baseline to 3 months, a significant reduction in ApoB concentration was observed with low-dose dabigatran (-0.057 (95% CI -0.069 to -0.044) g/L, p<0.001) and high-dose dabigatran (-0.065 (95% CI -0.078 to -0.053) g/L, p<0.001) but not warfarin (-0.006 g/L (95% CI -0.018 to 0.007) g/L, p=0.40). Compared with warfarin, ApoB reduction was significantly greater with both doses of dabigatran (p<0.001 for both groups). Reductions in ApoA1 concentrations did not statistically differ with either dose of dabigatran when compared with warfarin.

conclusionsDabigatran is associated with a significant (∼7%) reduction in ApoB concentration, suggesting a novel effect of this drug on lipoprotein metabolism. Further studies are needed to determine the mechanism of this observed effect, and its impact on clinical outcomes.

Indexed as

AgedAged, 80 and overAnticoagulantsApolipoprotein A-IApolipoprotein B-100BiomarkersBlood CoagulationDabigatranDown-RegulationDrug Administration ScheduleFemaleHumansInternational Normalized RatioLipid MetabolismMaleMiddle AgedAnticoagulantsAPOA1 protein, humanAPOB protein, humanApolipoprotein A-IApolipoprotein B-100BiomarkersDabigatranWarfarin

Identifiers

PMID26552755
OpenAlexW2109888925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.